Page 17 - Dyslipidaemia_newsletter8_2024_Final

REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #8 2024

10. Efficacy of combination therapy with statin and ezetimibe versus high dose statin monotherapy in secondary
prevention in high-risk patients. Halatiu VB, et al. Eur Heart J, Vol 45 (Suppl 1): ehae666.2842 Dyslipidaemia

SMALL TRIALS, TRIAL UPDATES, AND OTHER STUDIES ON LIPID THERAPY

11. Cardiovascular efficacy of evolocumab in patients with obesity: Updates from the FOURIER trial. Kang Y, et al.
Presented Sept 2, 2024 at the ESC Conference

12. Alternative LDL cholesterol lowering strategy vs. high-intensity statin strategy: An individual patient data meta-
analysis from the randomized RACING and LODESTAR trials. Hong M, et al. Presented at the 2024 ESC Conference

LIPIDS AS RISK FACTORS AMONG DIFFERENT POPULATIONS

13. Patient reported outcomes, control of hypertension and dyslipidemia: Results of two epidemiological studies in
Romania, conducted during pandemia (Snapshot-1) and post-pandemic (Snapshot-2). Ciobanu A, et al. Eur Heart J,
Vol 45 (Suppl 1): ehae666.2643

ACRONYMS:
ANOCA, angina with non-obstructive coronary arteries; ASCVD, atherosclerotic cardiovascular disease; ASO, antisense
oligonucleotide; BMI, body mass index; BP, blood pressure; CAD, coronary artery disease; CCS, chronic coronary syndrome;
CCTA, coronary computed tomography angiography; conc., concentration; CI, confidence interval; CRP, c-reactive protein; CV,
cardiovascular; CVD, cardiovascular disease; ECG, electrocardiogram; ED, emergency department; EZE, ezetimibe; FCT, free
combination treatment; FH, familial hypercholesterolaemia; GDMT, guideline-directed medical therapy; GLP-1, glucagon-like
peptide-1, HoFE, homozygous familial hypercholesterolaemia; HR, hazard ratio; INOCA, ischaemia with non-obstructive coronary
arteries; IR, incidence rate; LDL-C, low-density lipoprotein-cholesterol; Lp(a), lipoprotein(a); MI, myocardial infarction; NA, not
applicable; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor; PDC, Proportion of Days Covered; ROS, rosuvastatin;
SiRNA, small interfering ribonucleic acid; TC, total cholesterol; TG, triglycerides.

TABLE OF CONTENTS